BioSpace News Archive

Policy

CIVITAS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Civitas Solutions, Inc. - CIVI

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC, announces that KSF has commenced an investigation into Civitas Solutions, Inc. (NYSE: CIVI).

March 2, 2018
·
1 min read
CARsgen Completed $60 Million Pre-C Financing Framework Agreements

CARsgen Therapeutics announces it has entered into a Pre-C financing framework agreement with receiving $60M equity investment from existing and new investors.

March 2, 2018
·
1 min read
FDA

FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) of DUPIXENT® (dupilumab) as an add-on maintenance treatment in certain adults and adolescents (12 years of age and older) with moderate-to-severe asthma.

March 2, 2018
·
4 min read
Business

Philips and Hologic announce global partnership agreement to provide integrated imaging solutions for women’s health

Royal Philips and Hologic, Inc. announced a global partnership agreement to offer care professionals integrated solutions comprising diagnostic imaging modalities, advanced informatics and services for screening, diagnosis and treatment of women across the world.

March 2, 2018
·
3 min read
Genetown

Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis

Biogen and AbbVie announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis. The companies believe that characterizing the complex and evolving benefit/risk profile of ZINBRYTA will not be possible going forward given the limited number of patients being treated.

March 2, 2018
·
2 min read
Business

Revolutionary Robotic Treatment For Patients With Spinal Cord Injuries Now Available In United States

New advanced technology available at Brooks Rehabilitation, in partnership with Japan-based Cyberdyne, Inc.

March 2, 2018
·
4 min read
Pharm Country

Mylan to Introduce Two New Cost-Saving HIV Combination Treatments in the U.S.

Mylan will launch Symfi Lo and Cimduo at a significant discount to the price of competing products to bring cost savings to the $20 billion U.S. ARV market

March 2, 2018
·
7 min read
Business

ALSAC/St. Jude and LeMoyne-Owen College Open Call Center to Give Students Opportunity to Learn New Skills, Take Part in St. Jude Mission

ALSAC and LeMoyne-Owen College have together launched the LeMoyne-Owen College University Engagement Call Center, a St. Jude donor engagement facility, on the LeMoyne-Owen College campus.

March 2, 2018
·
1 min read
Business

ViTel Net Appoints Telehealth Executive Mark Noble as Senior Vice President of Business Development

ViTel Net announces Mark Noble, MBA, as Senior Vice President of Business Development.

March 2, 2018
·
2 min read
FDA

Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with standard review the company’s New Drug Application (NDA) seeking marketing approval for solriamfetol, an investigational medicine for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).

March 2, 2018
·
7 min read